New Delhi: Lupin Limited, a global pharmaceutical company has collaborated with Accenture to enable its data driven transformation journey for improved business agility, performance, and operational efficiency.
Accenture deployed a digital platform based on SAP S/4HANA, providing decision makers with real-time visibility into integrated data from multiple sources including supply chain, people and sales networks spread across 100+ countries and its fifteen manufacturing and research facilities in India, United States of America, Brazil and Mexico. The consolidated view of global business operations and performance has enabled informed decision-making.
“SAP Fiori apps have helped enhance the user experience for Lupin employees with simple and easy-to access data models and analytical reports,” the release stated.
“Lupin is committed to providing affordable healthcare to people across the world, and our data-driven digital platform will play a crucial role in this mission,” said Sreeji Gopinathan, CIO, Lupin. “Through our collaboration with Accenture, we will unlock the value of enterprise data in order to increase efficiencies and accelerate innovation across all our functions and processes, including manufacturing, testing, supply chain, and finance and accounting.”
Sameer Amte, lead for Accenture’s Life Sciences practice in India, said, “As Indian multinational pharmaceutical companies look at navigating supply chain disruptions and gaining a stronger foothold in the global economy, digital transformation will play a key role in advancing competitiveness by running more efficient business processes, improving research and development capabilities, and creating better customer experiences. With our deep industry experience and technology capabilities, we are helping Lupin become an intelligent enterprise by enabling data-driven decisions that will help accelerate product innovation and enable faster access to market.”
Lupin is a global pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.